Discuss your patients’ expectations of GORD management and assess their ongoing need for PPIs with the aim of stepping down treatment.
Up to 8 hours of Group 3 CPD (or 24 CPD credits)Toggle information
This activity has been accredited for the following CPD credits suitable for inclusion in an individual pharmacist's CPD plan:
- up to 2 hours of Group 1 CPD (or 2 CPD credits) upon the completion of reviewing the clinical guidance and/or pharmacist tools provided in the module;
- 5 hours of Group 3 CPD (or 15 CPD credits) upon the completion of reviewing the clinical guidance provided in the module, AND 5 episodes of care and reflection are completed (accreditation number: GN1807003A);
- 8 hours of Group 3 CPD (or 24 CPD credits) upon the completion of reviewing the clinical guidance provided in the module, AND 10 episodes of care and reflection are completed (accreditation number: GN1807003B).
Pharmacy Practice Reviews assist pharmacists to meet the following competency standards as set out in the Pharmaceutical Society of Australia Competency Standards for Pharmacists in Australia 2016:
- Standard 1.1 Uphold professionalism in practice
- Standard 1.4 Maintain and extend professional competence
- Standard 1.5 Apply expertise in professional practice
- Standard 1.6 Contribute to continuous improvement in quality and safety
- Standard 2.1 Collaborate and work in partnership for the delivery of patient centred, culturally responsive care
- Standard 2.2 Collaborate with professional colleagues
- Standard 2.3 Communicate effectively
- Standard 2.4 Apply interpersonal communication skills to address problems
- Standard 3.1 Develop a patient-centred, culturally responsive approach to medication management
- Standard 3.2 Implement the medication management strategy or plan
- Standard 3.3 Monitor and evaluate medication management
- Standard 3.5 Support Quality Use of Medicines
- Standard 3.6 Promote health and well-being
PPIs, as a class of medicines, are overprescribed, with data suggesting most of the PPIs prescribed in Australia are being used long term. Ongoing PPI use without a clear clinical indication could have more risks than benefit for the patient.
This Pharmacy Practice Review provides you with an opportunity to reflect on your support of patients who are using PPI medicines. Refresh your knowledge about long-term risks, adverse effects and other medicines that may make reflux symptoms worse. Review control of symptoms and identify patients who may benefit from stepping down their PPI treatment.
1) Express version: 5 episodes of care (for up to 15 CPD credits) or
2) Standard version: 10 episodes of care (for up to 24 CPD credits)
You will be given the option to submit your data once 5 episodes of care are entered, or continue to 10 episodes of care.
On completion of this activity, participants should be able to:
- Discuss GORD management expectations, including treatment and lifestyle modifications, with patients starting PPIs
- Assess ongoing need for PPI treatment at every encounter
- Use counselling techniques to support patients who may benefit from stepping down their PPI treatment
You will have access to:
- Up-to-date clinical guidance which provides evidence-based information to update your knowledge and guide your counselling encounters with patients
- Pharmacist tools that inform and support your best practice discussions with patients
- Expert commentary from Dr Geraldine Moses, BPharm DClinPharm Adv.Prac.Pharm FPS FACP AACPA MRPharmS